Get started
Author

Mehdi Fazal

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
2016 · John F R Robertson, Igor M Bondarenko, et al. · The Lancet · 584
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
2016 · Eric Van Cutsem, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 35
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer
2018 · John F.R. Robertson, Kwok-Leung Cheung, et al. · European Journal of Cancer · 23
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).
2009 · Swaminathan Padmanabhan, Joseph Thaddeus Beck, et al. · Blood · 22
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
2018 · Shinzaburo Noguchi, Matthew J. Ellis, et al. · Breast Cancer · 12
Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON).
2017 · John Forsyth Russell Robertson, Kwok-Leung Cheung, et al. · Journal of Clinical Oncology · 3
A phase I dose-escalation trial of TH-302 with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
2015 · Anthony J. Olszanski, Andrea Wang-Gillam, et al. · Journal of Clinical Oncology · 1
Works count: 7
Citation count: 680
H-index: 5
I10-index: 5
Year
Topic
Type